# Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win

> **Open Intelligence Dossier** · First detected: 2026-09-22 21:20 UTC · Category: Business

## Executive Summary
Amgen announces positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease.

## Intelligence Brief
Recent coverage from outlets including Reuters, Fierce Biotech, Endpoints News, Yahoo, FirstWord, Kalkine Media, GuruFocus, Investor&amp;#039;s Business Daily, and PR Newswire details a significant clinical development for Amgen. The company announced positive topline Phase 3 results for its autoimmune drug, a fusion protein acquired through Horizon. Specifically, the late-stage trial evaluated dazodalibep for patients suffering from moderate-to-severe systemic Sjögren&amp;#039;s disease. According to the reporting, the therapy successfully eased the severity of the condition in this initial Phase 3 trial, marking a major milestone for the therapeutic candidate. Financial and industry publications extensively covered the market and business implications of the clinical trial success.


Investor&amp;#039;s Business Daily noted that shares bounced higher following the announcement, while GuruFocus and Kalkine Media discussed shifts in the investment case and valuation for AMGN on NASDAQ following a 4.3 percent rally. Fierce Biotech and FirstWord both emphasized that the successful fusion protein originated from the Horizon acquisition, highlighting the strategic value of that corporate transaction for Amgen&amp;#039;s pipeline. The background established by the coverage centers on the clinical evaluation of dazodalibep as a treatment for systemic Sjögren&amp;#039;s disease, an autoimmune condition characterized by moderate-to-severe systemic involvement. The asset came into Amgen&amp;#039;s portfolio via the Horizon acquisition, making this late-stage trial success a critical test for the acquired pipeline. Prior to this announcement, market watchers and investors were closely monitoring the changing investment case for AMGN, as reflected in analyses from financial platforms discussing the stock valuation after the recent equity rally.


As coverage of the trial concludes initial reporting, future updates will depend on further disclosures from Amgen regarding subsequent trial phases, regulatory filings, and detailed data presentations. Current reports do not yet specify timelines for upcoming regulatory submissions or the exact schedule for presenting comprehensive trial datasets at upcoming medical congresses. Observers and market analysts will continue tracking how this late-stage success influences the broader valuation and performance of AMGN shares on NASDAQ.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Yahoo | First of Amgen’s Phase III Sjögren’s disease trials succeeds | [Source Link](https://news.google.com/rss/articles/CBMiiwFBVV95cUxOTDVLUWtqTlFielJtZFpKdk90bkoyNFNrUlJHcFpUYm5zZjdJZ1VEQmJzcDZaNHhKekY0c0RlczQya1RKVEJadmxWc3E4a3RvZFhocW9URklLYzVISmlCb29FQzVqN3BMYV9ESGROY3FqWE1FQndjWTFqck9BYVpld1EwUEhPYXJrYmtZ?oc=5) |
| FirstWord | Amgen's Horizon-sourced fusion protein succeeds in late-stage Sjögren's study | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE82R3Q4VW05NFFRdUJUTkJjV3BUT2pkcUo3Y1lkUl9tbWp4eHdacW5PN2loNUlwbzdHbjZZUl9fSG41Q2ZOLUdyUXQwSllydlA0SmYw?oc=5) |
| Kalkine Media | What is changing in the investment case for Amgen (NASDAQ:AMGN)? | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxPekdSRzVDMzJjaU8yY3lxcThsaDhEbXV3MktDN2dUUTh6V2lXUENsVFo0VEp2VHFiNWJyNlpRUG10Wi1Pd3FhNm53UmxxWFJBRC1ESklfU1ViSE1uVlJkTzVWcktwV21pckdtbThzOW43cU9HbmhxUTRGN0VpVjV5MFQyT2ZDMHlJMkJuNm1hLWhjN05MSW50cFZPRlBfNlF3SG5fTVduSHZFUQ?oc=5) |
| GuruFocus | Is Amgen Inc (AMGN) Overvalued After 4.3% Rally? GF Value Says O | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxOLUptdFhYdXBMMFkwOXp1RW5EMUU1VkxSU1hNeHpBRmI5RWpXUmtUV1BKSFo1Nzd4czg5Rl9TTTV3VXBvNVFpSkFhZWNvYlVoc2JTYVg5YW9seWxrUnpOd2VXQ0R5T0tBcVlKQmRiLTc2ejY4aE82Y2o1WkVhN2ZZTmdlU3J4RXhhOTRxZDRTbkEzVVh0WGFETm1nMjFoQ0MwQkNMTWRfUVlaYjQ?oc=5) |
| Amgen | AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE | [Source Link](https://news.google.com/rss/articles/CBMi9gFBVV95cUxOSHh6ZEExVXFEZHYyVnB3TTFwRnctZ2RqRVpBd0xGSFlVWnlxZDctUU9LN2hSVURzSkYtMHN3dVM0V1V1eU5rcnJpVE1Gek96QmlvU0I0N2Z2c2s0emtOOFBSX3NSa2RCZmthRlVkR2pOb0U3eWRRc0JDYWd4X05CanVwdkFtUkpqc1AxT3JtNU5lZGd6YjR4UDRlWHhzZE9fZkpWTU4tNVhrWlZmX3B5ZFdwdDVlRndJODE5dGdQSnlqV2p3OFdhRlNqMm9Za19hMlJENEVVaXVKSW9Wbm1IeHFDV0VaMVRUdkhoa01oNlFhdHloZWc?oc=5) |
| Investor's Business Daily | Amgen Boasts Success In Sjogren's; Shares Bound Higher | [Source Link](https://news.google.com/rss/articles/CBMiigFBVV95cUxOY3QycHltLTVCUW1NTUJ2eERIWWlfcUZUMnpFX1ZUaXdibWtodnVRd3RTTVNlMEFLa3JzeGg3UTk0SHZPZ29UTWtXOGwtMzMtckVpSmNsa3QzQ2RLWmx1R0pmeVEyek9PTWYwZE8zNWFwQVNZLXVRaWRNTkg1NDJTekdidWgydmFtSmc?oc=5) |
| PR Newswire | AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE | [Source Link](https://news.google.com/rss/articles/CBMi_AFBVV95cUxORkE0THhhQXo2aVVlbW9yVm5EcFVtc2VzeFJUS0YyQVhRNmdmcjJoNVZzdENNZ1FFQ2tiNlVERUhEaUtJdEFZZk1oaGJTVnpVU0VKOU1VMEljTzl3bVkxZlF2cDdGT29xZUlNNHFNZXJFSEFDdW1SWmZMbGFZVHRrUktORnRpOXZsNEJCc2ExMXV4b0h3TVcwakhTdERNcV9iVzlKUzJzU05UR3NJN3d6Yk5ObkpBZzhhcjZ2c1E5UVZfbDRVMURZYmhwdkJSZE1jYUlVaElzQWZwY3lnOHNpTEQ4bFdxVnVIUUhiRDNESE95SWlVNTVkdURJSDc?oc=5) |
| Endpoints News | Amgen’s Phase 3 Sjögren’s win; Novartis’ $900M radioligand deal | [Source Link](https://news.google.com/rss/articles/CBMiigFBVV95cUxOVEE4MHFFYkMxTnBwUmdKdkZvbnN6ZzFMLVE4NmtZVVJSTmZrRVhqZHZIODNNd2dyOVhxNm9fRFUteS13c1VDRE9RSGFzd3RodDB0UUNwdlozaWN3MUJHQ2NuYThaYUhEOE85bkdzWmZnMjRXYS1JQkNLYzFwSXdiT3p5OU9jMzZKWGc?oc=5) |
| Reuters | Amgen's autoimmune drug succeeds in late-stage trial | [Source Link](https://news.google.com/rss/articles/CBMivAFBVV95cUxPX25PclJ1Zk15TDJINlZ6LVhrSWdOcDJnandPUkpOZGxKLWJ2TGZQRzVHcUhOR25YX216SEFJZ2dLT21tdjZrNUI3MkVaMjVCX2ZiOUtTeHh1QXpyU3B4RVdkcmF2U01Bbk9vcXlsa1RFSUNzejFpc2plYmttZGFvcFZJZXRudFhxYkRwVmpnYjdhaDVBbTFscU03bHZ1STN2WTNFZndDZm02MEY0dWJIZXBFVUl2OEpzNXBPWA?oc=5) |
| Fierce Biotech | Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win | [Source Link](https://news.google.com/rss/articles/CBMirgFBVV95cUxNSklwVHRGU1VlejR0YkhHdWk4SC1samVyUmVUcWpDeTV5eEoyM0FoQk55c091VEVaMkFvNjZrM3FKQ0ZWT3VCV3RJMXAzU0lxMFdOOTQ5X3FXVnp4REd3U21DWVBNdEJGeDNzLXFCOHhrR0habUN5dkVzbUJKcll0RjIzTDlwMXQydWlnbkNldmp4Q2E0czF5WW45Nk5jaWNpWVZuTTAwLXNENG9FRWc?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-09-22/amgen-s-horizon-acquired-fusion-protein-eases-sjogren-s-severity-in-ph-3-win*
